Testing a new immune system treatment for rheumatoid arthritis and Sjögren's syndrome

Plain-English translation of NCT07712939 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

This is one of the first times this treatment has been tested in people.

What is this trial?

This is a Phase 1 trial testing a new medication called for the first time in humans. Researchers want to understand how safe the medication is, how the body processes it, and whether it might help people with rheumatoid arthritis or Sjögren's syndrome. The study starts with healthy volunteers and then moves to patients with these autoimmune diseases.

People with rheumatoid arthritis and Sjögren's syndrome experience severe joint pain, inflammation, and immune system problems that current treatments don't always control well. This trial is testing a new approach to managing the immune system that may offer relief to patients who need better treatment options.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old (if you're a healthy volunteer) or between 18 and 75 years old (if you have rheumatoid arthritis or Sjögren's syndrome)
you have been diagnosed with moderate to severe rheumatoid arthritis or primary Sjögren's syndrome (for the patient groups)
you are in generally good health with no active infections
you agree to use effective birth control during and after the study if you can become pregnant
you are willing and able to follow all study instructions

You likely don't qualify if…

you have had a severe allergic reaction to antibody-based medications in the past
you have an active infection or certain serious medical conditions
you have been diagnosed with cancer in the past 5 years
you are pregnant or breastfeeding
you have had major surgery in the past 12 weeks or are planning surgery during the study

What participation looks like

You would receive doses of the medication at study visits and have your blood tested regularly to monitor your safety and how your body responds. The study has two parts: the first part involves slowly increasing doses to find the safest dose, and the second part gives more people the medication at the dose that worked best. Visits include physical exams, blood work, and possibly other tests to check your health and immune system response.

AI-generated summary from trial data · Aug 3, 2026 · Not medical advice

Trial locations(1 site)

Australia

Candid Clinical Site, Melbourne, Victoria